公开(公告)号：US20180111997A1

公开(公告)日：2018-04-26

申请号：US15821595

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K31/404 ,  A61K39/395 ,  A61K38/20 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US09938316B2

公开(公告)日：2018-04-10

申请号：US14913366

申请日：2014-08-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Steven J. D. Karlish ,  Adriana Katz ,  Daniel M. Tal ,  Arie Marcovich

IPC: C07J43/00 ,  C07J19/00

CPC classification number: C07J43/003 ,  C07J19/005

Abstract: The present invention relates to digoxin and digitoxin derivatives that are selective inhibitors of the α2 isoform of Na,K-ATPase, and that reduce intra-ocular pressure. The invention further relates to uses of these derivatives for treating disorders associated with elevated intraocular pressure, such as glaucomas, and/or as cardiotonic agents.

公开(公告)号：US09902783B2

公开(公告)日：2018-02-27

申请号：US15161375

申请日：2016-05-23

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Tamar Danon ,  Netta Sela ,  Abraham Shanzer ,  Rina Arad-Yellin ,  Raghavendra Kikkeri

IPC: C07K16/44 ,  C07F3/06 ,  C07D233/61 ,  C07K16/40

CPC classification number: C07K16/44 ,  C07D233/61 ,  C07F3/06 ,  C07K16/40 ,  C07K2317/565 ,  C07K2317/76

Abstract: An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.

公开(公告)号：US20180053551A1

公开(公告)日：2018-02-22

申请号：US15562422

申请日：2016-03-30

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Barak DAYAN ,  Itay SHOMRONI ,  Serge ROSENBLUM

IPC: G11C13/04 ,  G11C7/00 ,  G02B6/35 ,  G02F1/01

CPC classification number: G11C13/04 ,  B82Y20/00 ,  G02B6/2746 ,  G02B6/35 ,  G02F1/01 ,  G02F1/0126 ,  G02F1/3521 ,  G02F2203/15 ,  G11C7/005

Abstract: A switch activated by a single control photon for routing a single target photon from either of two switch inputs to either of two switch outputs. The device is based on a single quantum emitter, such as an atom, coupled to a fiber-coupled, chip-based optical micro-resonator. A single reflected control photon toggles the switch from high reflection to high transmission mode, with no additional control fields required. The control and target photons are both in-fiber and practically identical, for compatibility with scalable architectures for quantum information processing.

公开(公告)号：US20180009893A1

公开(公告)日：2018-01-11

申请号：US15698800

申请日：2017-09-08

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2827 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61P25/16 ,  A61P25/28 ,  A61P27/02 ,  A61P37/06 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/76 ,  A61K2300/00

Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20170362296A1

公开(公告)日：2017-12-21

申请号：US15696206

申请日：2017-09-06

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yechiel SHAI ,  Avner FINK ,  Eliran-Moshe REUVEN ,  Liraz GALIA

IPC: C07K14/705 ,  C07K7/08 ,  C07K4/00 ,  A61K38/10 ,  A61K38/04 ,  A61K38/03 ,  C07K14/00 ,  A61K38/16 ,  A61K38/00

CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K38/03 ,  A61K38/04 ,  A61K38/10 ,  A61K38/16 ,  C07K4/00 ,  C07K7/08 ,  C07K14/00 ,  Y02A50/411

Abstract: Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.

公开(公告)号：US20170273917A1

公开(公告)日：2017-09-28

申请号：US15511033

申请日：2015-09-10

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Anthony FUTERMAN ,  Andres David KLEIN

IPC: A61K31/13 ,  G01N33/50 ,  A61K49/00 ,  C12Q1/68

CPC classification number: A61K31/13 ,  A61K9/0019 ,  A61K31/439 ,  A61K49/0004 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/50 ,  G01N33/5058 ,  G01N2800/28 ,  G01N2800/2842

Abstract: The present invention provides pharmaceutical compositions comprising at least one NMDA receptor antagonist for use in treating neuropathic forms of Gaucher Disease (nGD).

公开(公告)号：US20170268030A1

公开(公告)日：2017-09-21

申请号：US15611803

申请日：2017-06-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ron MILO ,  Lior ZELCBUCH ,  Niv ANTONOVSKY

IPC: C12P23/00 ,  C12N15/70 ,  C12N9/90 ,  C12N15/52

CPC classification number: C12P23/00 ,  C12N9/0004 ,  C12N9/001 ,  C12N9/0073 ,  C12N9/1085 ,  C12N9/90 ,  C12N15/52 ,  C12N15/67 ,  C12N15/70 ,  C12Y114/13129 ,  C12Y205/01 ,  C12Y205/01029 ,  C12Y505/01019

Abstract: A plurality of isolated polynucleotide sequences encoding enzymes of the astaxanthin pathway is disclosed. The polynucleotides include: (i) a polynucleotide which encodes Phytoene dehydrogenase (crtI) and a first transcriptional regulatory sequence; (ii) a polynucleotide which encodes Beta-lycopene cyclase (lcy-B) and a second transcriptional regulatory sequence; (iii) a polynucleotide which encodes Beta-carotene ketolase (crtW) and a third transcriptional regulatory sequence; and wherein the first, second and third regulatory sequence are selected such that the expression of the Icy-B and the crtW is greater than a level of expression of the crtI. Methods of generating astaxanthin using the plurality of polynucleotide are also disclosed as well as bacterial cells comprising high levels of astaxanthin.

公开(公告)号：US09764008B2

公开(公告)日：2017-09-19

申请号：US14398754

申请日：2013-05-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: A61K38/54 ,  A61K38/48 ,  C12N9/64

CPC classification number: A61K38/4886 ,  C12N9/6489 ,  C12Y304/24086 ,  Y02A50/473

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US20170240634A1

公开(公告)日：2017-08-24

申请号：US15125249

申请日：2015-03-12

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K31/4155 ,  A61K38/02

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.